ADIPOQ and COVID-19: A single study of similar size but with a younger population with lower mortality assessed circulating adiponectin in relation to mortality or respiratory failure and was unable to show an association between circulating adiponectin and admission to intensive care units or in-hospital death in patients hospitalized with COVID-19 [19].